Patten & Patten Inc. TN trimmed its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 6.0% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 6,155 shares of the exchange traded fund’s stock after selling 390 shares during the period. Patten & Patten Inc. TN’s holdings in SPDR S&P Biotech ETF were worth $554,000 at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in SPDR S&P Biotech ETF by 198.6% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 9,229,000 shares of the exchange traded fund’s stock worth $911,825,000 after purchasing an additional 6,138,000 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd acquired a new position in SPDR S&P Biotech ETF during the third quarter worth $141,284,000. Proficio Capital Partners LLC lifted its stake in SPDR S&P Biotech ETF by 16,156.1% during the fourth quarter. Proficio Capital Partners LLC now owns 917,329 shares of the exchange traded fund’s stock worth $82,615,000 after purchasing an additional 911,686 shares in the last quarter. Raymond James Financial Inc. acquired a new position in SPDR S&P Biotech ETF during the fourth quarter worth $55,529,000. Finally, J.Safra Asset Management Corp lifted its stake in SPDR S&P Biotech ETF by 461.6% during the fourth quarter. J.Safra Asset Management Corp now owns 292,502 shares of the exchange traded fund’s stock worth $26,293,000 after purchasing an additional 240,415 shares in the last quarter.
SPDR S&P Biotech ETF Stock Up 1.3 %
NYSEARCA:XBI opened at $87.13 on Monday. The stock’s fifty day moving average is $90.06 and its two-hundred day moving average is $94.78. SPDR S&P Biotech ETF has a 52 week low of $81.14 and a 52 week high of $105.47. The stock has a market capitalization of $5.65 billion, a price-to-earnings ratio of 11.47 and a beta of 0.99.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- The 3 Best Blue-Chip Stocks to Buy Now
- How to Build the Ultimate Everything ETF Portfolio
- Short Selling: How to Short a Stock
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What Are the FAANG Stocks and Are They Good Investments?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.